Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
About Ginkgo Bioworks Holdings Inc. (NYSE: DNA)
Ginkgo Bioworks Holdings Inc. is a pioneering company in the field of synthetic biology, operating a horizontal platform for cell programming that provides end-to-end solutions across diverse industries. Headquartered in Boston, Massachusetts, Ginkgo leverages its cutting-edge technologies to design, build, and test engineered organisms, addressing challenges in sectors such as pharmaceuticals, agriculture, industrial and specialty chemicals, and biosecurity.
Core Business Areas
Cell Engineering: The Cell Engineering segment is the cornerstone of Ginkgo's operations. Utilizing its proprietary Foundry platform, the company offers biological research and development services to customers. This includes engineering cells to produce specific molecules, optimize industrial processes, or develop new products. The Foundry integrates automation, high-throughput screening, and machine learning to streamline the design-build-test cycle, enabling scalable and cost-effective solutions.
Biosecurity: Ginkgo's Biosecurity segment provides critical services to government and commercial entities to identify, monitor, and mitigate biological threats. This includes solutions for pandemic preparedness, pathogen detection, and biosurveillance. By combining its expertise in synthetic biology with advanced diagnostics, Ginkgo supports public health and global biosecurity initiatives.
Platform Capabilities
Ginkgo's platform is underpinned by its extensive Codebase, a repository of biological data and engineered organisms, and its Foundry, which automates and accelerates the engineering of biological systems. The company's integration of artificial intelligence and machine learning enhances its ability to design complex biological systems, such as protein language models and genomic tools, further distinguishing its capabilities.
Industry Applications
- Pharmaceuticals: Ginkgo collaborates with biotech and pharmaceutical companies to accelerate drug discovery, optimize biologic manufacturing, and develop advanced therapies, including cell and gene therapies.
- Agriculture: The company partners with agricultural innovators to create sustainable solutions, such as bioengineered feed additives and crop protection products.
- Industrial Chemicals: Ginkgo designs microorganisms that produce specialty chemicals, enabling more sustainable and cost-effective manufacturing processes.
- Biosecurity: Through initiatives like pathogen detection and rapid diagnostics, Ginkgo plays a vital role in strengthening global health resilience.
Competitive Positioning
Ginkgo Bioworks differentiates itself through its horizontal platform model, which allows it to serve a wide range of industries with scalable and customizable solutions. Unlike vertically integrated competitors, Ginkgo's platform approach enables it to collaborate broadly, leveraging its expertise in synthetic biology to meet diverse customer needs. Its partnerships with entities like Google Cloud and global pharmaceutical leaders highlight its strategic positioning and technical capabilities.
Challenges and Opportunities
Operating in a highly regulated and competitive industry, Ginkgo faces challenges such as customer adoption, regulatory compliance, and market volatility. However, its focus on innovation, such as the development of AI-driven tools and biosecurity solutions, positions it to capitalize on emerging opportunities in synthetic biology and global health.
Conclusion
Ginkgo Bioworks Holdings Inc. stands at the forefront of synthetic biology, offering a unique platform that combines advanced engineering, automation, and biosecurity capabilities. By addressing complex challenges across multiple industries, Ginkgo continues to redefine the possibilities of biotechnology, making biology easier to engineer and more impactful for its partners and stakeholders.
Ginkgo Bioworks (NYSE: DNA) reported Q4 2024 results with total revenue of $44 million, up from $35 million year-over-year. Cell Engineering revenue grew 29% to $35 million, while Biosecurity revenue reached $9 million.
The company reported a Q4 GAAP net loss of $(108) million, improved from $(212) million in the prior year. Cash position stood at $562 million as of December 31, 2024, with Q4 cash flow of $(55) million, better than Q3's $(114) million.
For full-year 2024, total revenue decreased 10% to $227 million. The company achieved $190 million in annualized cost reductions and targets $250 million by Q3 2025. 2025 Guidance: Total revenue of $160-180 million, including Cell Engineering revenue of $110-130 million and Biosecurity revenue of at least $50 million.
Ginkgo Bioworks (NYSE: DNA) has integrated the Callisto™ Sample Prep System into their routine Illumina sequencing workflow. The system, developed by Volta Labs, addresses the automation challenges in DNA clean-up processes, particularly for high-throughput labs handling thousands of samples.
The Callisto system features an App Store concept that enables access to multiple sequencing technologies and chemistries on a single platform, helping maintain low operating costs. A notable addition is the Size Selection app, which allows short-read labs using Illumina, Element Biosciences, and Ultima Genomics platforms to purify and select optimal fragment sizes for sequencing.
The system's advanced electrowetting, magnetic, and acoustic capabilities, along with its proprietary VoltaNode™ technology, enable precise liquid separation, efficient DNA elution from beads, and flexible batch processing.
Ginkgo Bioworks (NYSE: DNA) has announced a partnership with the European Health and Digital Executive Agency (HaDEA) in a consortium project worth up to €24 million over 4 years. The project, named RANGER (RApid Next Generation Sequencing for Effective Medical Response), aims to develop a rapid point-of-care diagnostic solution for respiratory viruses.
The initiative will create a device capable of identifying virtually any respiratory pathogen through metagenomic next-generation sequencing (mNGS) with a 6-hour turnaround time. The program includes an option for the European Commission to procure 200 devices at preferred pricing.
The project will be executed in three phases, involving technology development with partners Jumpcode, TGen, Bugseq, and Planet Innovation, followed by clinical trials in EU hospitals, and finally EU certification. The consortium includes partnerships with KU Leuven, Karolinska University Hospital, and Tartu University Hospital for clinical trials.
Ginkgo Bioworks (NYSE: DNA) has scheduled its Q4 and full year 2024 financial results presentation for Tuesday, February 25, 2025, at 5:30 p.m. ET. The presentation will include a business performance review and Q&A session.
Investors can access the presentation and webcast through Ginkgo's investor relations website, with a replay option available afterward. Questions can be submitted in advance via X (using #GinkgoResults) or email to investors@ginkgobioworks.com.
Ginkgo Bioworks (NYSE: DNA) has announced its 2025 Ferment Series, transforming its annual conference into multiple focused events throughout the year at their Boston Seaport District venue. The series will showcase Ginkgo's cell engineering and biosecurity offerings, featuring presentations from company experts, partners, and industry leaders.
The events will highlight new products and services, including Ginkgo Datapoints' AI-driven data generation services, Ginkgo Automation's Reconfigurable Automation Cart systems, and Ginkgo Biosecurity's product suite featuring Canopy and Horizon platforms.
The series includes four main events: Summer's Datapoints x AI focus on biotech R&D, September's Biopharma Solutions showcase, October's Biosecurity discussions, and November's Automation demonstrations. Additionally, Ginkgo will participate in World AgriTech in San Francisco (March) and ABIM (October), including a tour of their West Sacramento R&D facility. A larger, platform-wide Ferment will return in 2026.
Ginkgo Bioworks (NYSE: DNA) announced that its Ginkgo Automation division will design and deploy a flexible laboratory automation system for the Great Lakes Bioenergy Research Center (GLBRC) at the University of Wisconsin–Madison. The system aims to support biofuels and bioproducts research from plant biomass.
The new anaerobic-capable automation system will enable GLBRC scientists to run multiple experiments simultaneously across both aerotolerant and anaerobic conditions, increasing efficiency and 'walkaway' time. The system includes access to Catalyst Flow, a remote error resolution service expected to resolve 80-90% of system errors without user intervention.
Built on expertise from Ginkgo Bioworks and Zymergen, the customizable system focuses on automating workflows for anaerobic organisms, a key requirement for GLBRC's research programs. The technology aims to help GLBRC advance its mission of enabling cost-effective, sustainable biofuel production at scale.
Ginkgo Bioworks (NYSE: DNA) has announced a research collaboration with Universal Cells, an Astellas company, to optimize next-generation induced pluripotent stem cell (iPSC)-derived cancer cell therapies. The partnership aims to enhance the potency and persistence of iPSC-derived immune cell therapeutics for solid tumors.
The collaboration combines Universal Cells' proprietary iPSC-derived cell technologies with Ginkgo's expertise in design and screening large CAR libraries and its high-throughput, multimodal immune cell engineering platform. Ginkgo's approach utilizes computational tools, library assembly and screening expertise, and statistical analysis to accelerate therapeutic design optimization.
The platform enables simultaneous testing of numerous CAR designs from transcriptome to cell function, focusing on improving immune cell persistence and functionality. This partnership represents a significant expansion of Ginkgo's cell therapy portfolio.
Ginkgo Bioworks (NYSE: DNA), a company focused on cell programming and biosecurity, announced that its Co-Founder and CEO Jason Kelly will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Thursday, January 16, 2025, at 10:30 a.m. PT (1:30 p.m. ET). A webcast link and replay will be available on the company's investor relations website.
Ginkgo Bioworks (NYSE: DNA) has been awarded a $9.4 million subcontract in partnership with Carnegie Mellon University to develop bioelectronic cell-based devices for treating hormone disorders under ARPA-H's REACT program. The BIO-INSYNC project focuses on creating implantable devices that can produce therapeutic molecules and monitor disease biomarkers in real-time for at least one year after implantation.
The initiative will initially target thyroid disorders, developing systems to measure thyroid hormone levels and produce required doses. Patients and healthcare providers will be able to monitor and control the treatment via smartphone. The project combines Ginkgo's expertise in mammalian cell and iPSC engineering with Carnegie Mellon's bioelectronics capabilities, along with researchers from the University of Pittsburgh, University of Florida, and UC Santa Cruz.
Ginkgo Bioworks (NYSE: DNA) reported Q3 2024 financial results with total revenue of $89 million, up 61% year-over-year, including a $45 million non-cash revenue from deferred revenue release. Excluding this impact, revenue was $44 million, down 21%. Cell Engineering revenue decreased 20% to $30 million, while Biosecurity revenue fell to $14 million. The company reported a Loss from operations of $(55) million and Adjusted EBITDA of $(20) million. Ginkgo updated its 2024 guidance to $215-235 million in total revenue. The company achieved cost reductions through restructuring, estimating over $85 million in annualized savings by mid-2025.
FAQ
What is the current stock price of Ginkgo Bioworks Holdings (DNA)?
What is the market cap of Ginkgo Bioworks Holdings (DNA)?
What does Ginkgo Bioworks do?
How does Ginkgo Bioworks generate revenue?
What industries does Ginkgo Bioworks serve?
What makes Ginkgo Bioworks unique?
What is Ginkgo's Foundry platform?
What is the role of AI in Ginkgo's operations?
What are the challenges Ginkgo Bioworks faces?
Who are Ginkgo's competitors?
What is Ginkgo's role in biosecurity?
How does Ginkgo collaborate with other companies?
